Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Publications and Abstracts

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events
American Association for Cancer Research (AACR) Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference

American Association for Cancer Research (AACR) Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference

A comparison of mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harbouring wild-type and mutant p53

Oct 19, 2015

16th World Conference on Lung Cancer, Denver, Colorado

Tuesday, September 8, 2015 poster session. Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer

Sep 8, 2015

GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain

Tuesday, September 8, 2015 poster session. Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma

Sep 8, 2015

ASCO Annual Meeting, Chicago, Illinois

Monday, June 1, 2015 poster session. Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma Multiforme (GBM)

Jun 1, 2015

106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania

Monday, April 20, 2015 poster session: VAL-083 Phase 1/2 data poster # CT217: Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma

Apr 20, 2015

106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania

Monday, April 20, 2015 poster session: VAL-083 GBM preclinical poster #2562: Dianhydrogalactitol inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo

Apr 20, 2015

106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania

Sunday, April 19, 2015 poster session: VAL-083 NSCLC preclinical poster # 751: In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer

Apr 19, 2015

VAL-083: GBM Historical Review & Strategy for Product Development

Feb 1, 2015

DelMar Preclinical Research Presented at Society for NeuroOncology Annual Meeting

Nov 14, 2014

DelMar in vitro data from SNO: Differentiation from Temozolomide

Nov 14, 2014
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next »
© 2023 Kintara Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences